Screener
Amneal Pharmaceuticals, Inc. AMRX Specialty — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 / Affordable Medicines | Three Months Ended June 30, 2026 / Specialty | Three Months Ended June 30, 2025 / Affordable Medicines | Three Months Ended June 30, 2025 / Specialty |
|---|---|---|---|---|
| Employee compensation and benefits | $12,016 | $1,326 | $14,693 | $1,279 |
| Materials and supplies | 8,796 | 1,022 | 8,108 | 450 |
| Product development and studies (1) | (89) | 2,615 | 756 | 2,371 |
| In-licensing and upfront milestones | 3,500 | — | 6,350 | — |
| Facilities costs | 1,479 | 30 | 1,793 | 735 |
| Regulatory fees | 1,334 | — | 2,932 | — |
| Other (2) | 5,987 | 1,001 | 7,267 | 1,230 |
| Total | $33,023 | $5,994 | $41,899 | $6,065 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s specialty — research and development expense?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — research and development expense of $5.99M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — research and development expense changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — research and development expense decreased by 1.2% year-over-year, from $6.07M to $5.99M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — research and development expense?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — research and development expense has grown at a -8.7% compound annual growth rate (CAGR), from $43.48M to $30.16M.
- What does specialty — research and development expense mean?
- Measures the investment in scientific research, clinical trials, and product development aimed at expanding or improving the specialty pharmaceutical product pipeline. This metric reflects the company's commitment to long-term innovation and future revenue potential. It is a key indicator of the segment's ability to sustain a competitive advantage through new therapeutic offerings.
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude